- Terumo BCT invests in Hemex Health to enhance Hb variant testing access.
- Chetan Makam joins Hemex's Board to strengthen collaboration.
- Focus areas include clinical research, digital integration, and regional pilots.
- Hemex's Gazelle™ is key for identifying Hb types linked to sickle cell disease.
Investment and Collaboration
Terumo Blood and Cell Technologies has made a strategic minority investment in Hemex Health to improve access to hemoglobin variant testing. This move aims to address the challenges faced by millions with sickle cell disease and other hemoglobin disorders, particularly in regions with limited testing availability.
Board Appointment
Chetan Makam, General Manager of Global Blood Solutions at Terumo BCT, has been appointed to Hemex Health's Board of Directors. This appointment is expected to enhance collaboration between the two companies and explore new opportunities for advancing their shared strategy.
Focus Areas
The collaboration will focus on clinical research, digital integration, and regional pilots to expand access to Hemex Health’s Gazelle™, a tool for identifying and quantifying hemoglobin types in the blood. This is crucial for early treatment and ongoing assessment of treatment impact.
Challenges and Goals
In many regions, access to hemoglobin variant testing is limited, delaying diagnosis and treatment for millions. The partnership aims to bridge this gap by improving monitoring and treatment, ultimately delivering timely care to underserved communities.
